Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Share-based Compensation (2021 - 2025)

Aligos Therapeutics' Share-based Compensation history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 14.49% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.0 million, down 40.31%, while the annual FY2025 figure was $5.0 million, 40.32% down from the prior year.
  • Share-based Compensation reached $1.5 million in Q4 2025 per ALGS's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q2 2022 to a low of $959000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $2.7 million, with a median of $3.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: grew 15.84% in 2022, then crashed 63.78% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.7 million in 2021, then dropped by 6.44% to $3.4 million in 2022, then decreased by 24.39% to $2.6 million in 2023, then plummeted by 33.99% to $1.7 million in 2024, then decreased by 14.49% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Share-based Compensation are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.2 million (Q2 2025).